乳腺癌PD-L1（SP142）表達與臨床病理特徵關係分析

A study on PD-L1(SP142) expression and its correlation with clinicopathological features

韋潔貞(WAI Kit Cheng)；冼麗芳(SIN Lai Fong)；林文華(LAM Man Wa)；陳建勇(CHAN Kin Iong)；黃香婷(WONG Heong Ting)；文劍明(WEN Jian Ming)

乳腺癌 ； 三陰乳腺癌 ； PD-L1 ； 免疫治療 ； Breast cancer ； TNBC ； PD-L1 ； Immunotherapy

鏡湖醫學

21卷1期（2021 / 06 / 01）

27 - 29+i

繁體中文;英文

目的：探討程序性死亡配體-1（PD-L1）在乳腺癌免疫細胞（IC）中的表達及與臨床病理特徵的關係。方法：收集鏡湖醫院乳腺癌標本，按乳腺癌分子分型分為三陰乳腺癌（TNBC）、管腔A型、管腔B型及HER2型，採用免疫組化檢測各型乳腺癌PD-L1（SP142）表達情況，並分析其與臨床病理特徵的關係。結果：136例乳腺癌中，TNBC50 例、管腔A型42例、管腔B型15型、HER2型29例。全部病例中，PD-L1（SP142）陽性（≥1% IC）44 例（32.4%）。TNBC的PD-L1（SP142）陽性率（48%）明顯高於管腔A型（11.9%），管腔B型（20%），和HER2型（41.4%）。PD-L1（SP142）的表達與組織學分級和增殖指數相關（P <0.001），而與年齡、病理TNM分期、淋巴結轉移、臨床分期無關。結論：PD-L1（SP142）表達的TNBC病人適用於PD-L1免疫治療。

Objective: To detect PD-L1 expression inimmune cells (IC) of breast cancer and analyze the relationship between the PD-L1 expression and clinicopathological features. Methods: Breast cancer were collected in Kiang Wu Hospital and divided into 4 groups according to molecular classification:triple negative breast cancer (TNBC), Luminal A, Luminal B and HER2-enriched. PD-L1 (SP142) was detected by immunostaining. The relationship between PD-L1 (SP142) expression in breast cancer and clinicopathological features was analyzed. Results: Among 136 cases of breast cancer, there were 50 cases of TNBC (36.8%), 42 Luminal A (30.9%), 15 Luminal B (11%) and 29 HER2 (21.3%). In total cases of breast cancer,44 cases (32.4%) were PD-L1 (SP142) positive (≥1% IC). PD-L1 (SP142) positive rate in TNBC (48.0%) was significantly higher than Luminal A (11.9%), Luminal B(20%) of and HER2-enriched (41.4%) (P<0.01). The expression of PD-L1(SP142) in breast cancer was correlated with histological grade and proliferation index (P<0.001), but not with age, pTNM stage, lymph node metastasis or clinical stage. Conclusion: The TNBC patients with PD-L1 (SP142) expression were suitable for PD-L1 immunotherapy.